Myostatin (MSTN) is a transforming growth factor (TGF)-β superfamily member that acts as a
negative regulator of muscle growth and may play a role in cardiac remodeling. We …

Following myocardial infarction (MI), the heart undergoes a pathological process known as
remodeling, which in many instances results in cardiac dysfunction and ultimately heart …

Abstract Background Myostatin (Mstn) is a key regulator of heart metabolism and
cardiomyocyte growth interacting tightly with insulin-like growth factor I (IGF-I) under …

Activin type II receptor (ActRII) ligands have been implicated in muscle wasting in aging and
disease. However, the role of these ligands and ActRII signaling in the heart remains …

Signaling through activin receptors regulates skeletal muscle mass and activin receptor 2B
(ACVR2B) ligands are also suggested to participate in myocardial infarction (MI) pathology …

Prior studies have shown that overexpression of ACT A can lead to ventricular remodeling in
rat models of heart failure. Furthermore, recently work studying demonstrated that …

The transforming growth factor-β (TGF-β) superfamily member, myostatin, is a negative
regulator of muscle growth and may contribute to adverse cardiac remodeling. Whether …

Myostatin, a member of the TGF-β superfamily of secreted growth factors, is a negative
regulator of skeletal muscle growth. In the heart, it is expressed at lower levels compared to …

Activin A has been linked to cardiac dysfunction in aging and disease, with elevated
circulating levels found in patients with hypertension, atherosclerosis, and heart failure …

Myostatin (MSTN), a negative regulator of muscle growth and size, is increased after acute
myocardial infarction (AMI) but timing of upregulation after injury is not known. In this study …